Largest Ibuprofen API maker eyes double revenue in next four years

The latest IOL chemicals and pharmaceuticals ltd news is that we are diversifying our API and specialty chemicals portfolios. As part of the plan, we are also investing ₹300 crore to set up a plant in western India. The aim is to double sales in the next 5 years. As a leading pharma APO manufacturing company, we generate about 30% of our revenues from the commodity API ibuprofen. As part of the portfolio expansion, we are targeting commodity products such as paracetamol and metformin and specialty chemical products such as fenofibrate.